Nine-month interim report (Q3) 2007

To the Copenhagen Stock Exchange
Translation	Announcement no. 18 • 2007
November 22, 2007

Nine-month interim report (Q3) 2007
(unaudited)

Financial performance in the nine months ended September 30, 2007
(Comparative figures for the same period last year are shown in brackets)

- Revenue increased to DKK 1,209 million (1,103) 
- Organic growth in sales of allergy vaccines was 17% 
- Sales of GRAZAX® totalled DKK 30 million
- Operating profit (EBIT) was DKK 207 million (a loss of 1) and included an
up-front payment from the company's US partner Schering-Plough of DKK 199
million 
- Profit before tax (EBT) was DKK 218 million (17) 
- Profit for the period was DKK 164 million (0)

Highlights of the period
The authorities in Greece, Norway and Finland have decided to provide full
public reimbursement for treatment with GRAZAX®, joining the group of countries
that have decided to provide reimbursement for the tablet. 

The regulatory authorities' decisions on whether to provide reimbursement for
treatment with GRAZAX® in a number of countries are taking longer than
originally anticipated. ALK-Abelló expects that the launch of GRAZAX® in all
the company's own markets will not have been completed until in the first half
of 2008. The long-term commercial potential and perspective of the product in
the European markets is unchanged, and interest in GRAZAX® among physicians
remains high. 

Outlook for the 2007 financial year unchanged 
For the financial year 2007, ALK-Abelló retains its forecast of revenue,
including revenue from sales of GRAZAX®, of DKK 1,650-1,700 million (1,519).
The forecast of the rate of organic growth in sales of allergy vaccines is
retained at 15-19%. The forecast of operating profit (EBIT) is retained at DKK
200-220 million and includes revenue from Schering-Plough of DKK 199 million.
The forecast of pre-tax profit (EBT) remains unchanged at DKK 230-250 million. 

Hørsholm, November 22, 2007
ALK-Abelló A/S


Contact:
Jens Bager, President and CEO, tel +45 4574 7576. 


ALK-Abelló holds a conference call for analysts and investors today at 3.30
p.m. (CET) at which Jens Bager, President and CEO, and Jutta of Rosenborg, CFO,
will review the results. Danish participants must call in on tel +45 7026 5040
before 3.25 p.m. (CET), and international participants must call in on tel +44
208 817 9301 before 3.25 p.m. (CET). The conference call will also be webcast
on our website: www.alk-abello.com, where the related presentation will be
available shortly before the conference call begins.